| abstract |
The present invention relates to Tat as an active basis for a prophylactic and / or therapeutic vaccine against HIV infection, its development to AIDS, and the development of tumors and other syndromes and symptoms in subjects infected with HIV. Tat is in a biologically active form, either as a recombinant protein or peptide, or as DNA. More specifically, the invention relates to an HIV-1 Tat vaccine as an immunogen inoculable as DNA and / or recombinant protein or peptides, alone or in combination with other genes or viral gene products (Nef, Rev, Gag) or parts thereof, or in combination with various immunomodulatory cytokines (IL-12, IL-15), or with a gene encoding an immunomodulatory cytokine or part thereof. Tat, Nef, Rev, Gag and immunomodulating cytokines are administered either as a mixture of recombinant proteins, peptides, or complex proteins (Tat / Nef, Tat / Rev, Tat / Gag, Tat / IL-12, Tat / IL-15), or in the form of plasmid DNA. |